This study concerns the expression of biomarkers involved in diverse pathways, such as progression, DNA repair mechanisms and angiogenesis to establish an immunoprofile capable of characterizing sporadic versus familial breast cancers (BCs). The aim was to identify a patient subgroup with a different clinical outcome, which could then be directed towards new targeted therapies. Hierarchical cluster analysis (HCA) was carried out using the immunohistochemical score from tissue microarray sections of an initial cohort of 183 (88 sporadic and 95 familial) patients with invasive BC. For the survival analysis, only those patients with complete follow-up were considered. The HCA revealed a 16-protein immunoprofile, nine of which represent the core, as was also found when familial and sporadic BCs were analysed individually. The 16-biomarker immunoprofile was able to identify a group of patients (Group 1) with a more aggressive tumour phenotype. Survival analyses showed that VEGF In conclusion, we found that tumour stratification based on an immunoprofile is useful to predict the patient clinical behaviour. In particular, our study indicates that the clustering of tumors on the basis of this immunoprofile suggests the possibility to differentiate familial from sporadic BCs and to clinically select those patients who are more likely to benefit from inhibition of the VEGF pathway.
One of the main aims of breast cancer (BC) research is to reduce the morbidity and mortality associated with the disease. Cancer onset and progression are the result of a multistep process which leads, in the last phase, to metastatic development. In this dynamic process it is possible to intervene in the various phases, from the surveillance of populations at risk to the identification of specific treatment for invasive BC cases, by relying on specific prognostic and predictive markers. 1 BC is an heterogeneous disease, including different biological entities and subtypes with specific pathologic characteristics and diverse clinical behaviour. 2 Moreover, it may involve a hereditary component related to the transmission of a mutated tumour suppressor gene, even if quite rare (5-10% of BCs); BRCA1 and BRCA2 mutations are found in 30-40% of familial BC cases. 3 Thus, the stratification of BC into clinically relevant subgroups is necessary for patient prognosis and treatment selection. 4 Some immunohistochemical biomarkers, such as hormonal receptors, proliferative index and human epidermal growth factor receptor 2 (HER2), together with tumour size, tumour grade, nodal involvement, histological type and surgical margins, have all been widely utilized for stratification of BC patients, prognosis, prediction, and selection of therapies. thus underlying the necessity to identify novel biomarkers, or their combination, to permit a more accurate prediction of treatment response and prognosis.
Recently, we characterized a group of familial invasive BC patients by analysing the immunohistochemical expression of different biomarkers on tissue microarray (TMA) sections, and by hierarchical cluster analysis (HCA). 6 Together with the biomarkers routinely used in the diagnostic setting, we investigated certain proteins involved in various other biological pathways. In particular, from among the progression markers, the Na 1 /H 1 exchanger regulatory factor 1 (NHERF1), together with its subcellular nuclear and cytoplasmic localization, was examined and it was previously related to BC patient outcome. 7 In addition, the markers involved in the epithelial to mesenchimal transition (EMT), such as TWIST1 and Claudins, and the CD44 and CD24 stem cell markers were also considered. All of these represent the hallmarks of invasion and metastasis, contributing to poor prognosis. 8 Biomarkers involved in DNA repair mechanism, such as BRCT-repeat inhibitor of hTERT expression (BRIT1), SWItch 5 (SWI5), BRCA1 and Poly [ADP-ribose] polymerase 1 (PARP1), are suitable candidates involved in the carcinogenic pathway, both for familial and sporadic BCs. 9 Moreover, also angiogenesis is necessary for the growth and invasiveness of breast tumours by means of several different mechanisms; angiogenic factors are now considered as therapeutic targets for selective inhibitors. 10 Several biomarkers involved in the angiogenic pathway, such as the vascular endothelial growth factor receptor 1 (VEGFR1), the vascular endothelial growth factor (VEGF), the hypoxia inducible factor-1 alpha (HIF-1a) and microvessel density (MVD) were also included in the study. An immunoprofile was obtained consisting of 10 proteins, characterized by the low expression of the estrogen receptor (ER), progesterone receptor (PR), BRCA1, nuclear NHERF1 and HIF-1a, and also by the higher expression of MIB1 (for proliferative index), cytoplasmic NHERF1, cytoplasmic BRIT1, VEGF and VEGFR1, able to identify a subgroup of familial BC patients with a more aggressive tumour phenotype also associated with a larger tumour size and G3 grade. 6 On the basis of these previous results, the present study aimed to evaluate the presence of a specific immunophenotype which would be useful to differentiate the sporadic from familial BC type, and to identify a subgroup of patients with a different clinical outcome which could be directed towards new targeted therapies. Therefore, the analyses were performed by HCA regarding the expression of NHERF1, TWIST1, Claudin 1, Claudin 4, BRIT1, SWI5, BRCA1, PARP1, VEGFR1, VEGF, HIF-1a, MVD, CD44 and CD24, in addition to the markers commonly used in clinical practice.
Materials and Methods

Patients and tissues
A cohort of 183 patients, 95 with familial and 88 with sporadic invasive breast tumours were retrospectively enrolled in the study. The patients, with a median age of 49 years (range 24-83 years), were subjected to primary surgery with nodal dissection at the Institute IRCCS Istituto Tumori "G. Paolo II" of Bari, Italy, in the years 2002-2003. The tumours were classified as "familial" on the basis of the criteria identified during patient genetic counselling as previously described.
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All patients provided informed consent to utilize their removed biological tissue for molecular analyses and research purposes, according to ethical standards. The study was approved by the Ethics Committee of Istituto Tumori "G. Paolo II" with the reference number 56/CE signed on May 16, 2011 .
The characterization of the tumours according to size, lymph node status, grade, perineoplastic invasion, ER, PR, proliferative activity and HER2 status (Table 1) was provided by the Pathology Department of our Institute. Tumours with ER or PR expression were classified as positive when nuclear staining was found in >10%. MIB1 nuclear staining was used to assess the proliferative activity, with a cut off value of 20% positive cells to indicate the tumours with MIB1 >20% as highly proliferating. This cut off is the median value of scores relative to all breast tumour samples analysed during these years within our Institute. HER2 protein expression was studied using a monoclonal antibody (MoAb clone CB11; Novocastra Laboratories, Ltd., Newcastle, UK) and scored in accordance with the HercepTest scoring system (Food and Drug Administration): 0 indicated no membranous immunoreactivity or <10% of cells reactive; 11, an incomplete membranous reactivity in >10% of cells; 21, 10% of cells with weak to moderate complete membranous reactivity; and 31, strong and complete membranous reactivity in >10% of cells. Cytoplasmic immunoreactivity was ignored. Cases scoring 0
What's new? Breast cancer is a heterogeneous disease and novel biomarkers are necessary for a more accurate prediction of treatment response and prognosis. Here, the authors analyzed the expression of potential biomarkers involved in diverse pathways such as cancer progression, DNA repair mechanisms, and angiogenesis in addition to the markers commonly used in clinical practice. They found a 16-protein immunoprofile with nine core proteins able to identify a patient group with a more aggressive tumor phenotype. The combined and different expression of VEGF and TWIST1 also differentiated familial from sporadic breast cancers and identified a patient group with a worse disease-free survival. and 11 were classified as negative. HER2 was considered to be positive if immunostaining was 31 or if a score 21 showed gene amplification by fluorescence in situ hybridization (FISH). In FISH analyses, each copy of the HER2 gene and its centromere 17 (CEP17) reference was counted. The interpretation was in accordance with the criteria of 2007 ASCO/CAP guidelines for HER2 testing in BC, 12 therefore positive if the HER2/CEP17 ratio was higher than 2.2.
TMAs and IHC
TMAs were constructed manually from formalin-fixed and paraffin-embedded tissues, according to standard procedures as previously described. 13 In brief, tumour target areas were selected from one donor block per patient, three 0.5 mm cores were punched out and transferred to the recipient TMA blocks. The TMA blocks were cut in sections which were stored at 48C-88C until analysed. Each sample was arrayed in triplicate to minimize tissue loss and to overcome tumour heterogeneity; thus the three cores were representative of the whole specimen. All immunostained samples were scored by double-blinded independent observers who had no patient outcome and clinicopathological data information, and the mean of the three readings for each patient was calculated. If one core was uninformative, lost or contained no tumour tissue, the overall score applied was that of the remaining cores. The results from two observers were identical in most cases, and discrepancies were resolved by reexamination and consensus. All specimens were cut into 4-mm-thick slices to make sections for immunohistochemical staining using standard immunoperoxidase techniques.
14 In brief, TMA slides were deparaffinised and partially rehydrated through absolute ethanol and 95% ethanol series. Antigen retrieval was performed by the 0.01 M citrate buffer (pH 6.0) at 988C in a water bath from a minimum of 20 to a maximum of 45 min, except for the anti-Claudin 1 antibody which requires antigen retrieval by the Tris/EDTA buffer (pH 8.0) at 988C in a water bath for 45 min. The slides were then allowed to cool for 30 min and the endogenous peroxidase activity was blocked for 10 min with 3% H 2 O 2 . The primary antibodies, diluted in PBS/ BSA 1%, were incubated on the slides at 48C overnight in a moist chamber. For anti-VEGFR1, 1 hr incubation at room temperature was required. A polymer-based IHC detection system was used as the amplification system (EnVision 1 System-HRP Labelled Polymer Anti-Rabbit or AntiMouse secondary antibody, Dako, Carpinteria, CA, USA) according to the manufacture's instruction. The bound antibody was visualized by incubating the sections in 3-amino-9-ethylcarbazole (AEC 1 Substrate Chromogen, Dako, Carpinteria, CA, USA) for 15 min, except for anti -CD34, -VEGFR1, -BRCA1, -PARP1, -Claudin 1 and -Claudin 4 which require the use of 3,3 0 -diaminobenzidine (Liquid DAB 1 Substrate Chromogen System, Dako, Carpinteria, CA, USA) for 8-10 min. Cell nuclei were counterstained with Mayer's Haematoxylin (Bio-Optica, MI, Italy) and the slides were mounted with aqueous mounting medium (Faramount Aqueous Mounting Medium, Dako, Carpinteria, CA, USA).
The different analysed biomarkers, dilution, source/clone, the staining localization of antibody and the cut off [median value, immunohistochemical score (IHS) or quickscore method (QS)] used to classify positive versus negative cases are shown in Supporting Information Table S1 .
NHERF1 immunostaining was predominantly cytoplasmic (cNHERF1), however in some cases an intense nuclear (nNHERF1) staining was also demonstrated. This was scored separately and its significance was evaluated. BRIT1 also showed a cytoplasmic (cBRIT1) or nuclear (nBRIT1) staining, which was scored separately. The median value of immunoreactive cells was used as cut off for cNHERF1 (40%), 
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nNHERF1 (>0%), TWIST1 (4%), Claudin 1 (>0%), Claudin 4 (>0%), cBRIT1 (15%), nBRIT1 (>0%), SWI5 (10%), BRCA1(>0%), VEGFR1 (>0%), HIF-1a (>0%) and MVD (15%). For VEGF, the HIS was calculated by combining the quantity score (percentage of positive stained cells) with the staining intensity score. 15 The quantity score ranged from 0 to 4: 0 5 no immunoreactivity; 1 25% cells stained; 2 5 26-50% cells stained; 3 5 51-75% cells stained; and 4576% cells stained. The staining intensity was scored as: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). Raw data were converted to IHS by adding the quantity score (0-4) to the staining intensity score (0-3). Theoretically, the scores can range from 0 to 7. An IHS of 6-7 was considered a strong immunoreactivity; 3-5, moderate; 1-2, weak; and 0, negative. For our analyses, tumours presenting a moderate or strong score were VEGF positive (IHS:3-7). PARP1 immunoreactivity was scored by the multiplicative QS. 16, 17 This system accounts for both the intensity and the extent of cell staining. The proportion of positive cells was estimated and given a score on a scale from 1 to 6 (1 5 1% to 4%, 2 5 5% to 19%, 3 5 20% to 39%, 4 5 40% to 59%, 5 5 60% to 79%, and 6 5 80% to 100%). The average intensity of the positive staining of cells was provided a score from 0 to 3 (0 5 no staining, 1 5 weak, 2 5 intermediate, and 3 5 strong staining). A final score was calculated by multiplying the percentage score by the intensity score. Based on the final score, PARP1 expression was graded as negative (0-9) or positive (10-18). The tumour was considered positive for CD44 and CD24 biomarkers when a moderate to strong staining was observed in >10% (cut off) of tumour cells, as per previous publications. 18, 19 Finally, microvessel counting was performed by identifying the areas which represented the highest vascular density, the so called "hot spots". The MVD measurements were made in the fields with a higher density of CD-34 positive cells and cell clusters at 2003 magnification, as previously described. 15 Positive and negative controls were included in each staining run as indicated in the data sheet of each antibody. The accuracy, reliability, scoring strategy and reproducibility assessments of these antibodies have been validated in previous studies already published. 6, 7, 9, [13] [14] [15] [16] [17] [18] [19] Hierarchical clustering and statistical analyses
Unsupervised HCA was performed using the immunohistochemical score data of each biomarker by means of the same approach adopted for cDNA microarray data. 20 The javabased tool GENE-E (http://www.broadinstitute.org/cancer/ software/GENE-E/index.html) was used to carry out clustering, merging objects based on their pair-wise distance. The average linkage method was used to obtain cluster dendrograms both for biomarkers and cases, which could be seen respectively on the left side and top of the heatmap. A strong positive score is represented by a red block and a negative score appears as a blue block. Non-evaluable stains are represented by grey blocks.
The Fisher's exact test was assessed in order to evaluate the correlations between the two groups of patients identified by HCA, with the clinicopathological tumour characteristics (size, lymph node status, grade and perineoplastic invasion), to determine which biomarkers contributed to the formation of cluster groups and to evaluate the distribution of the more significant biomarkers in each HCA patient group respect to the familial or sporadic BC status. Statistical analyses were performed using SPSS 17.0 software (SPSS, Inc, Chicago, IL, USA). Univariate and multivariate analyses were carried out to correlate immunomarkers with clinicopathological features. A generalized linear model was fitted through the glm() function of R package "MASS". The clustered patient groups were assessed in relation to Disease-free survival (DFS). DFS (in months) was defined as the time from diagnosis to the date of the first locoregional or distant recurrence, second invasive breast carcinoma, the appearance of a second primary invasive cancer, and/or to the date of death without evidence of cancer or to the date of last visit. DFS probability of the clustered patient groups was computed by the Kaplan-Meier product limit method and compared by the log rank test. Survival analysis was performed through GraphPad Prism 5.0.1. The "survival" R-package was used to fulfill Cox regression analysis taking into account DFS. Results from all statistical analyses were considered to be significant at a level of pvalues <0.05.
Results
Protein expression profiling
The tumour characteristics of the 183 patients enrolled in this study are reported in Table 1 . The immunohistochemical expression of NHERF1, TWIST1, Claudin 1, Claudin 4, BRIT1, SWI5, BRCA1, PARP1, VEGFR1, VEGF, HIF-1a, MVD, CD44 and CD24 (Supporting Information Table S1 ) was evaluated on TMA sections. In Table 2 , the frequency of expression of these biomarkers within the entire cohort of tumour samples is reported. Only 13/183 (7.1%) BCs had the CD44 positive/CD24 negative phenotype that defines BC stem cells. 21 Moreover, the frequency of expression of the same proteins was also detailed in the 88 cases of sporadic BC and in the 95 cases of familial breast tumour (Table 2) .
Supporting Information Figure S1 outlines with a flow chart the principal analyses performed in our study.
Analyses of sporadic breast tumours
The unsupervised HCA was performed firstly considering only the sporadic patients with >20% of evaluable biomarkers. In this analysis, we included the markers object of the study (cNHERF1, nNHERF1, TWIST1, Claudin 1, Claudin 4, cBRIT1, nBRIT1, SWI5, BRCA1, PARP1, VEGFR1, VEGF, HIF-1a, MVD, CD44, CD24), in addition to markers routinely used in clinical practice (ER, PR, MIB1 and HER2), in order to organize score data into groups based on similarity and dissimilarity of the immunostaining profiles. The analysis included 65 of 88 (73.9%) sporadic patients. The dendrogram obtained defined two patient clusters characterized by two different clusters of biomarkers (Cluster 1 and Cluster 2). In detail, Cluster 1 included ER, PR, HIF-1a, TWIST1, nNHERF1, BRCA1, nBRIT1, and CD44; Cluster 2 included cNHERF1, VEGF, HER2, SWI5, cBRIT1, CD24, VEGFR1, MVD, PARP1, MIB1, Claudin 1 and Claudin 4. One group of patients (A) was characterized by the underexpression of Cluster 1 and the overexpression of Cluster 2, while the other patient group (B) demonstrated the opposite behaviour (Fig. 1a) . The distribution of each biomarker between the two patient groups was analysed in order to determine the biomarkers which contributed in a significant manner to discriminate the two groups. A statistically significant difference was found for ER (p < 0.006), PR (p < 0.020), MIB1 (p < 0. Abbreviations: cNHERF1, cytoplasmic NHERF1; nNHERF1, nuclear NHERF1; cBRIT1, cytoplasmic BRIT1; nBRIT1, nuclear BRIT1.
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Analyses of the entire cohort of familial and sporadic breast tumours
In a second phase, all cases of sporadic and familial BC with >20% of evaluable biomarkers, corresponding to 141 of 183 (77%) patients, were considered for a new HCA.
The new dendrogram obtained defined two sample clusters (Group 1 and Group 2), characterized by two clusters of biomarkers (Cluster 1 and Cluster 2). In detail, Group 1 included 91 patients, 53 with familial and 38 with sporadic BC, while Group 2 was composed of 50 patients, 23 with familial and 27 with sporadic BC. Moreover, Cluster 1 included ER, PR, nNHERF1, nBRIT1, HIF-1a, BRCA1, TWIST1, and PARP1 biomarkers; Cluster 2, on the other Table S2 . Therefore, the immunoprofile obtained consisted of 16 biomarkers, 9 of which (ER, PR, MIB1, cNHERF1, nNHERF1, VEGF, VEGFR1, HIF1 and BRCA1) were the same also obtained for familial, as previously reported, 6 and sporadic BCs, both analysed individually, while the other 7 (cBRIT1, nBRIT1, TWIST1, HER2, SWI5, Claudin 4 and CD44) resulted significant when familial and sporadic BCs were analysed together. Figure 3a shows the immunohistochemical expression on TMA sections of some of the 9 proteins, representing the core immunoprofile.
Regarding the clinicopathological features, tumour size and grade showed a statistically significant difference (p 5 0.007 and p < 0.001, respectively) when we compared Group 1 and Group 2. When referring to familial or sporadic breast tumour type, on the other hand, there was no statistically significant association between the two patient groups.
Univariate and multivariate analyses were performed taking into account Group 1 and Group 2 patients concerning the clinicopathological characteristics. Univariate regression analysis revealed that tumour size >2 cm (odds ratio (OR) 5 3.33, 95% confidence interval (CI) 1.35/8.33, p 5 0.009) and G3 grade (OR 5 7.14, 95% CI 2.5/25, p 5 0.0005) were both associated with Group 1, while multivariate analysis identified the presence of perineoplastic invasion (OR 5 1.20, 95% CI 0.43/3.45, p 5 0.006) as an independent variable for the Group 1 (Supporting Information Table S3 ).
With regards to patient outcome, complete follow up was available only for 94/141 (66.7%) patients with a median time of 109 months. Thirty patients experienced cancer recurrence. There was no statistically significant difference in DFS Kaplan-Meier curves between patients of Group 1 and Group 2 (p 5 0.22) (Fig. 2b) . However, the median DFS of Group 1 was 77 months compared to 102 months of Group 2. To note, however, that 21 patients with cancer relapse were clustered in Group 1 with respect to the other 9 patients who were included in Group 2.
Multivariate analysis with respect to DFS, including the 16 immunomarkers which represented the immunoprofile, revealed that the VEGFR1 positive expression was an independent predictor for a shorter DFS (Hazard Ratio (HR)51.33, 95% CI 1.01/1.76, p 5 0.02).
Comparison of the 16 biomarker-immunoprofile between familial and sporadic breast tumours
In order to better clarify the significance of the immunoprofile consisting of 16 biomarkers obtained by the second HCA, we performed Fisher's exact test in Group 1 and Group 2 patients with respect to the familial and sporadic BC status.
As shown in Table 3 -expression resulted to be associated to familial BCs and nNHERF1 1 expression to sporadic ones (p 5 0.045). As VEGF and TWIST1 expression (Fig. 3b) resulted significantly associated to the sporadic and familial BCs, but in opposite way, it was decided to analyse these relationships considering the patient clinical outcome. Regarding the DFS analysis, as expected, familial BC VEGF 1 patients of Group 1 had a worse DFS compared to the sporadic BC VEGF -patients of Group 2, even though the statistical significance was not reached (p 5 0.09) (Fig. 2c) . The Kaplan-Meier curves, however, revealed that there was no statistically significant result (p 5 0.106) when comparing the DFS of Group 1 familial BC TWIST1 -patients with the DFS of Group 2 sporadic BC TWIST1 1 patients (Fig. 2d) . In addition, the DFS analysis showed that the VEGF 1 /TWIST1 -familial BC patients of the Group 1 tended to have a lower DFS than sporadic BC patients of Group 2 with VEGF -/TWIST1 1 expression (p 5 0.052) (Fig. 2e) . The result reached a statistical significance when we compared by log rank test, the DFS of all patients (N 5 29) with simultaneously VEGF 1 and TWIST1 -expression with respect to the DFS of all patients (N 5 22) with VEGF -and TWIST1 1 expression (p 5 0.034) (Fig. 1f) .
Discussion
The present study was performed with the purpose of identifying an innovative immunoprofile to characterize the sporadic and familial breast tumours in order to distinguish subgroups of patients with differing prognoses.
When considering only sporadic BC patients, the HCA identified an immunoprofile including 9 biomarkers (ER, PR, MIB1, cNHERF1, nNHERF1, VEGF, VEGFR1, HIF-1a and BRCA1). This same panel was also found in familial BC patients, characterizing the tumours with a more aggressive behaviour associated with a larger size and grade G3. 6 In sporadic BC patients, on the other hand, this immunoprofile was not associated with the same aggressive tumour clinicopathological characteristics. In addition, the expression of HER2, TWIST1 and nBRIT1, which also resulted significantly distributed, probably characterized only the patients with sporadic BC, since they were not significant biomarkers in the familial BC analysis. 6 The panel of 9 biomarkers formed a core immunoprofile able to discriminate BC patients into two different groups, as it was also confirmed when sporadic and familial BC patients were analysed together. However, in this last case, the lower expression of ER, PR, nNHERF1, HIF-1a and BRCA1 along with the higher expression of MIB1, cNHERF1, VEGF and 
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VEGFR1 identified the group of patients with a more aggressive tumour clinicopathological characteristics: large size, G3 grade and the presence of perineoplastic invasion. These patients also had a shorter median DFS.
In the present paper, the HCA revealed that, in all BCs, the immunoprofile consisted in these 9 biomarkers, but also in other 7 proteins (cBRIT1, nBRIT1, TWIST1, HER2, SWI5, Claudin 4 and CD44) which resulted in a significantly different distribution between the two groups of patients (Group 1 and Group 2). In this context, it was interesting to theorize if some of them might be associated with the familial or sporadic BC status.
It is known that BC is an heterogeneous disease and cancer arising in carriers of mutated BRCA1 and BRCA2 genes differs from sporadic BC and from familial non-BRCA1/2 tumours. 22 The identification of specific biomarkers which are differentially expressed in sporadic and familial BCs might be useful to further characterize these types of tumours and to evaluate their prognostic behaviour.
Our results show that two biomarkers, namely VEGF and TWIST1, were significantly distributed between sporadic and familial BCs, and also in the opposite manner. Familial BC patients were positive for VEGF and negative for TWIST1, while sporadic BC patients were negative for VEGF and positive for TWIST1.
VEGF is one of the most important factors taking part in physiological and pathological angiogenesis. Its overexpression in tumour cells plays an important role in malignant transformation, promoting invasion and metastasis 23 and is related with shorter DFS. 24 Many tumours, such as BC, 25 also express VEGFR, and in this setting VEGF acts through an autocrine signalling pathway, independent of angiogenesis, but promoting proliferation, survival, adhesion and migration. 26 TWIST1 is an important activator of EMT and plays a key role in tumour promotion and progression by enhancing cancer cell motility and dissemination. Angiogenesis and tumour progression are closely linked to one another. 27 In fact, it was found that upregulation of TWIST1 may play an important role in the angiogenesis of breast carcinoma, besides its involvement in tumour progression, and also resulted in elevated expression of functional VEGF. 28 However, even if tumour angiogenesis in BC could be activated by TWIST1-VEGF signalling axis, the molecular mechanism of TWIST1 in angiogenesis in human cancer is still not fully understood. 29 Our findings highlight that the opposite expression of these two biomarkers was strictly associated to a different status of BC, supporting the evidence that familial and sporadic breast tumours are two different entities. 22 However, when we analysed the expression of each single biomarker for association with familial or sporadic BC status (VEGFR Thus we can speculate that the familial BC patients had a more aggressive behaviour and tended towards a worse prognosis than sporadic BC patients. However, in the combined expression of VEGF and TWIST1, we can also hypothesize that the positive expression of VEGF had a major impact on patient outcome compared to the positive expression of TWIST1. This result apparently contrasts with the finding that the higher expression of TWIST1 protein, reported in different human Tumor Markers and Signatures cancers 30 and also in BC, was associated with a more aggressive breast tumour phenotype and with a worse prognosis for DFS and OS. [31] [32] [33] [34] In our study, the overexpression of TWIST1 was more frequent in sporadic than in familial BCs, thus a possible biological mechanism on its basis could not be excluded, since its role in BC development and progression remains largely unknown. Moreover, also the crosstalk between these two biomarkers in relation to their angiogenic and metastatic functions require further studies, also considering that their expression showed the opposite behaviour in familial with respect to the sporadic BCs.
However the VEGF pathway appeared to be useful for prognosis of BC patients also considering that our findings showed that the VEGFR1 positive expression was an independent predictor for a shorter DFS.
In conclusion, we evidence that the patient stratification on the basis of an immunoprofile is useful to predict the clinical behaviour of BC patients, and it might be helpful to also differentiate familial from sporadic BC patients. In particular, the clustering of these patients on the basis of the immunoprofile found in our study could be applied in clinical practice to select the patients for whom antiangiogenic therapy would represent an effective treatment. The capability to stratify those BC patients who are more likely to be responsive to bevacizumab is clinically relevant to improve the efficacy of the drug and to rationalize the costs of therapy.
